Europe In Vitro Fertilization Market Expected to Reach $4,447 Million

Fertility services are services availed by people who are unable to conceive naturally. These services help infertile couples, single parents, and LGBT community to procreate and start a family. In vitro fertilization and other assisted reproductive technology (ART) procedures, surrogacy, and artificial insemination are some of the widely executed fertility services.

The fertility service market is anticipated to grow considerably in the near future owing to different factors such as increase in infertility rates, changes in lifestyle, and surge in incidence of male infertility cases. Low awareness with respect to fertility services in emerging markets restrict the market growth. Rise in prevalence due to increase in risk factors, such as obesity, stress, polycystic ovarian syndrome (PCOS), sexually transmitted infections, endometrial tuberculosis, and other medical conditions, is expected to offer lucrative opportunities for market growth during the forecast period.

The European IVF Market was valued at $3,054 million in 2015 and is estimated to reach $4,447 million by 2022, growing at a CAGR of 5.4% during the analysis period.The IVF market in Europe is characterized by factors such as lower fertility rates, delayed marriages, and late parenthood decisions. Subsidization of IVF treatments in Germany owing to the lowest birthrate of ~1.46 children/women is a major driving factor for the growth of this market. In addition, the National Health Plan (NHP) covers about 50% of the total treatment cost and pays for three IVF cycles, which is expected to boost the IVF market, especially in Germany. However, lack of reimbursements and high cost of the procedure limit the growth of the European IVF market.

The emerging trend of delayed pregnancies and increasing average age of parenthood over the last decade are major factors that drive the growth of the IVF market. France has witnessed a rise in trend in same-sex couples seeking parenthood. In addition, polygamy and polyandry have also increased, though to a lesser extent, increasing the demand for alternative reproductive treatments. Countries such as UK have recently accepted three-parent IVF methods, commonly banned in other countries worldwide. This method is expected to boost the growth of UK IVF market owing to its inherent benefits of avoiding gene-linked mitochondrial DNA diseases in newborns.

The growth in government interventions and support, especially in UK where lower fertility, aging population, and lack of workforce have triggered severe implications, is further expected to boost the market growth. Government support and regulations (such as HFEA act and guidelines), favorable policies such as three-parent IVF, and availability of reimbursements are expected to drive the UK IVF market growth at a CAGR higher than rest of the European countries.

The report provides extensive competitive analysis and profiles of key market players, such as Apollo Hospitals Enterprise Ltd, Care Fertility Group, Carolinas Fertility Institute, Genea Limited, The Johns Hopkins Health System Corp, Medicover Group, Monash IVF Group, OvaScience Inc., Progyny Inc., and Xytex Cryo International The other players in the value chain (not included in the report) include Irvine Scientific, INVO Bioscience, LifeGlobal Group, and IVFtech ApS.

Focused Points

  • Drug Results for In Vitro Fertilization
  • What are the costs of in vitro fertilization?
  • What are the success rates for in vitro fertilization?
  • Acupuncture for In Vitro Fertilization?
  • Infertility and Reproduction
  • Overview
  • Symptoms
  • Diagnosis & Tests
  • Treatment & Care
  • Support & Resources

Reset Password